–Tafamidis approved by ANVISA for peripheral neuropathy: First pharmacological treatment approved in Brazil for FAP patients, marking significant progress in non-surgical management. CEPARM was the only Brazilian center involved in the international trial.– CEPARM's coordinator, Márcia Waddington, President of Scientific Committee of THAOS (2016–2019): Recognized globally with her appointment to the scientific committee of THAOS, a pivotal database to improve FAP treatment. Here, FAP is linked to peripheral neuropathy.